Diversas alterações genéticas estão associadas à patogênese do carcinoma epidermoide (CE), neoplasia maligna mais comum de cabeça e pescoço. Algumas dessas alterações comprometem proteínas pertencentes à via de sinalização do Akt, envolvida em diferentes fenômenos celulares. Este trabalho teve como objetivo estudar a expressão da proteína pAkt em linhagens celulares de carcinomas epidermoides de cabeça e pescoço, de forma a verificar possíveis alterações na transcrição dessa molécula em células de CE tratadas com Curcumina. Foram utilizadas duas linhagens celulares de CE de cabeça e pescoço (FaDu e SCC9) e uma linhagem de queratinócitos normais (HaCat) divididas em dois grupos: a. Grupo controle não tratado; b. Células tratadas com Curcumina. A proliferação celular foi monitorada através do teste de viabilidade celular e a análise da expressão de proteína foi realizada através da técnica do Western Blotting que revelou supressão do pAkt na linhagem celular SCC9 nos tempos de 24 e 48 horas. Desta forma, conclui-se que a Curcumina na via do Akt em carcinomas epidermoides de cabeça e pescoço tem importante ação supressora do gene pAkt. / Several genetic alterations are associated with the pathogenesis of squamous cell carcinoma (SCC), the most common malignant neoplasm of the head and neck. Some of these changes compromise the proteins belonging to the Akt signaling pathway, involved in various cellular phenomena. The objective of this study to explores the expression of the pAkt protein in cell lines of the squamous cell carcinomas of the head and neck to verify possible changes in the transcription of this molecule in EC cells treated with curcumin. The study used two cell lines of EC head and neck (FaDu and SCC9) and a normal line of keratinocytes (HaCat), split into two groups: A. the controlled group, untreated; B. Cells treated with curcumin. The cell proliferation it was observed by cell viability test and analysis of protein expression performed through Western blotting technique revealed suppression of pAkt in SCC9 cell line at 24 and 48 hours. Thus, it is concluded that the Curcumin on the path of Akt in squamous cell carcinoma of the head and neck has a significant suppressive effect of gene Akt.

A leucemia linfoide aguda (LLA) é uma neoplasia hematológica agressiva, caracterizada pela expansão clonal de progenitores linfoides e ativação exacerbada de vias de sinalização. A via de sinalização de IGF1R/IRS1 inicia-se pela ligação do ligante IGF1 ao seu receptor transmembrana IGF1R, e subsequente ativação de seu substrato IRS1, que transmite sinais mitogênicos e antiapoptóticos, principalmente através da modulação das vias de sinalização PI3K/AKT/mTOR e MAPK . Estas vias de sinalização desempenham uma importante função na proliferação, sobrevivência e migração de células de leucêmicas. Dessa forma, o objetivo do nosso trabalho foi investigar a participação da via de sinalização IGF1R/IRS1 na LLA. Linhagens celulares Jurkat, MOLT-4, Namalwa e Raji foram tratadas ou não com inibidor de IGF1R/IRS1-2, NT157, ou com inibidor de IGF1R/IR, OSI-906, e submetidas à avaliação da viabilidade celular, apoptose, proliferação, ciclo celular, migração e expressão/ativação gênica e proteica. Células mononucleares de pacientes com LLA e de doadores saudáveis foram submetidas aos ensaios de viabilidade e apoptose, após tratamento com NT157 e OSI-906. O efeito do NT157 in vivo foi avaliado utilizando modelo de xenotransplante de células CEM em camundongos NSG. O estudo foi aprovado pelo Comitê de Ética em Pesquisa e Comitê de Ética no Uso dos Animais da Instituição. A análise estatística foi realizada pelo teste ANOVA e teste t de Student. O tratamento com NT157 reduziu a viabilidade e a proliferação, induziu apoptose e modulou o ciclo celular em todas as linhagens testadas (p<0,05). Similarmente, OSI- 906 reduziu a viabilidade e a proliferação, modulou o ciclo celular, porém não foi capaz de induzir apoptose nas linhagens de LLA (p<0,05). Os tratamentos com NT157 e com OSI-906 diminuíram significativamente a migração de Jurkat em fibronectina, porém não modularam a migração de Namalwa. Em um contexto molecular, a exposição ao NT157 resultou em inibição da fosforilação de proteínas da via de sinalização PI3K/AKT/mTOR e modulou a expressão de 25 genes relacionados com a via de sinalização MAPK, dentre eles CDKN1A (p21), FOS e JUN (p<0,05). OSI-906modulou a ativação das proteínas da via de sinalização PI3K/AKT/mTOR e a expressão gênica de p21, FOS e JUN, porém de uma forma diferente da modulação encontrada pelo tratamento com NT157 (p<0,05). Em células mononucleares de pacientes com LLA, NT157 induziu uma resposta heterogênea na viabilidade e induziu apoptose, e OSI-906 reduziu a viabilidade, porém não foi capaz de induzir apoptose nestes pacientes (p<0,05). Os tratamentos com NT157 e OSI-906 não apresentaram citotoxicidade em células de doadores saudáveis. Adicionalmente, o tratamento in vivo com veículo ou NT157 na dose de 50mg/kg/dia, via intraperitoneal, em modelos de xenotransplante com células CEM em camundongos NSG (n=5 para cada grupo) não apresentou efeitos antineoplásicos. Em conclusão, a inibição farmacológica de IGF1R/IRS1-2, por NT157, e de IGF1R/IR, por OSI-906, apresentaram efeitos antineoplásicos significativos em modelos de linhagens celulares e amostras primárias de pacientes com LLA. Os resultados dos estudos in vivo em modelos de xenotransplante indicam a necessidade de estudos de farmacocinética e farmacodinâmica para o NT157. Nossos resultados revelaram que NT157 exerce um efeito citotóxico nas células de LLA, enquanto que OSI-906 tem um efeito predominantemente citostático. Estes dados indicam que o inibidor de IGF1R/IRS1-2, NT157, obteve resultados antineoplásicos mais atrativos e a inibição direta de IRS1 pode ser um potencial alvo terapêutico em LLA. / Acute lymphoid leukemia (ALL) is an aggressive hematological neoplasm, characterized by clonal expansion of lymphoid progenitors and exacerbated activation of signaling pathways. The IGF1R/IRS1 signaling pathway initiated through binding of the ligand IGF1 to its transmembrane receptor IGF1R, and the subsequent activation of its substrate IRS1, which transmit mitogenic and antiapoptotic signals, mainly through the modulation of the PI3K/AKT/mTOR and MAPK signaling pathways. These signaling pathways play an important function in cell proliferation, survival and migration of leukemia cells. Therefore, the objective of our study was to investigate the participation of the IGF1R/IRS1 signaling pathway in ALL. Jurkat, MOLT-4, Namalwa and Raji cell lines were treated or not with IGF1R/IRS1-2 inhibitor, NT157, or with IGF1R/IR inhibitor, OSI-906, and evaluated for cell viability, apoptosis, proliferation, cell cycle, migration, gene and protein expression/activation. Mononuclear cells from patients with ALL and from healthy donors were submitted to the viability and apoptosis assays, after treatment with NT157 and OSI-906. The NT157 effect in vivo was evaluated using CEM cell line xenograft model in NSG mice. The study was approved by the Research Ethics Committee and the Ethics Committee on the Use of Animals of the Institution. Statistical analysis was performed by ANOVA and Student t test. Treatment with NT157 reduced viability and proliferation, induced apoptosis, and modulated the cell cycle in all cell lines tested (p<0.05). Similarly, OSI-906 reduced viability and proliferation, modulated the cell cycle, but was not able to induce apoptosis in ALL cell lines (p<0.05). Treatments with NT157 and OSI-906 significantly decreased the migration of Jurkat in fibronectin, but did not modulate the Namalwa migration. In a molecular context, the NT157 exposure resulted in inhibition of the PI3K/AKT/mTOR signaling pathway protein phosphorylation and modulated the expression of 25 genes related to the MAPK signaling pathway, including CDKN1A (p21), FOS and JUN (p<0,05). OSI-906 modulated the activation of the PI3K/AKT/mTOR signaling pathway proteins and the p21, FOS and JUN geneexpression, but in a different way from the modulation found by treatment with NT157 (p<0.05). In mononuclear cells of patients with ALL, NT157 induced a heterogeneous response in viability and induced apoptosis, and OSI-906 reduced viability, but was not able to induce apoptosis in these patients (p<0.05). Treatments with NT157 and OSI- 906 did not show cytotoxicity in healthy donor cells. Additionally, in vivo treatment with vehicle or NT157 at the dose of 50 mg/kg/day, intraperitoneally, in xenotransplantation models with CEM cells in NSG mice (n=5 for each group) showed no antineoplastic effects. In conclusion, the pharmacological inhibition of IGF1R/IRS1- 2, by NT157, and IGF1R/IR, by OSI-906, showed significant antineoplastic effects in cell line models and in primary samples of patients with ALL. The results of in vivo studies in xenotransplantation models indicate the need for pharmacokinetic and pharmacodynamic studies for NT157. In conclusions, our results revealed that NT157 exerts a cytotoxic effect on ALL cell lines and primary ALL cells, whereas OSI-906 has a predominantly cytostatic effect. These data indicate that the IGF1R/IRS1-2 inhibitor, NT157, obtained more attractive antineoplastic results and the direct inhibition of IRS1 may be a potential therapeutic to target in ALL.

La doxorubicine (DXR) est l’un des médicaments les plus efficaces en chimiothérapie, mais sonapplication clinique est limitée par ses effets cardiotoxiques. Malgré des décennies de recherche, sesmécanismes pathogéniques ne sont toujours pas entièrement compris. Il s’ensuit qu’aucun traitementsatisfaisant, curatif ou préventif, n’existe. Dans cette étude, nous recherchons les mécanismes designalisation cellulaire impliqués. Deux modèles expérimentaux de toxicités, aigue d’une part (coeurisolé et perfusé de rat avec la DXR), et chronique d’autre part (rat traité à la DXR), ont permis deréaliser une étude ciblée (sur les voies de signalisation énergétiques) et deux études systémiques(phosphoprotéomique et transcriptomique). Les résultats combinés de ces travaux ont montré que laDXR modifiait le niveau de phosphorylation (activation) ou l’expression génique de protéinesimpliquées dans trois domaines fonctionnels distincts : métabolisme énergétique, réponses au stress,et structure/fonction du sarcomère. (i) Métabolisme énergétique : nous avons confirmé la surprenanteinhibition de l’AMPK, probablement provoquée par un contrôle négatif exercé par des partenaires designalisation (Akt et ERK), plutôt que par une modification des kinases activatrices en amont. Nousavons également montré l’augmentation du niveau de phosphorylation de la PDH, ce qui, en inhibantl’enzyme, ralentit le cycle de Krebs. Cependant, nous avons également observé un phénomènecompensatoire de surexpression de gènes codant pour des enzymes de la glycolyse et du cycle deKrebs ; (ii) Réponses au stress : dans nos modèles, la DXR génère des stress énergétique,génotoxique et oxydatif. Cependant, seuls quelques mécanismes compensatoires sont activés (lesvoies de signalisation de DNA-PK–Akt–GSK3, diverses chaperonnes). Les autres semblent êtreinhibées suggérant que l’amoindricement des réponses au stress serait un des mécanismes de lacardiotoxicité de la DXR; (iii) Structure/fonction du sarcomère: L’augmentation de la phosphorylationde la desmine ainsi que la réduction du nombre de transcrits codant pour des protéines essentiellesau développement cardiaque normal pourraient être la cause de la désorganisation du réseaumyofibrillaire. En conclusion, ces résultats révèlent potentiellement de nouveaux mécanismes de lacardiotoxicité induite par la DXR et permettent d’envisager de nouvelles cibles moléculaires pour ledéveloppement de stratégies protectrices. / Doxorubicin (DXR) is an efficient anticancer drug, the use of which is limited by seriouscardiotoxicity. Despite decades of research, its pathogenic mechanisms are not fully understood, andefficient preventive or curative strategies are not available. Here we address the question whethermechanisms in cardiac cell signaling contribute to the toxicity phenotype. Using experimental modelsfor acute (DXR-perfused, isolated rat hearts) or chronic toxicity (rats injected with DXR), we conducteda targeted study (focusing on energy signaling pathways) and two non-biased studies(phosphoproteomics and transcriptomics). The combined data reveal DXR-induced alterations inphosphorylation (activation) status or gene expression of proteins in mainly three functional domains:energy metabolism, stress responses, and sarcomere structure. (i) Energy metabolism: We confirm aparadox inhibition of AMPK signaling, that is rather due to inhibitory cross-talk with related signalingpartners (Akt, ERK) than impaired AMPK upstream signaling. We also show, among others, theincrease of inhibitory phosphorylation of pyruvate dehydrogenase, slowing down Krebs cycle, but alsoa compensating upregulation of glycolysis and Krebs cycle enzyme transcripts. (ii) Stress-responses:In our models, DXR generates energetic, oxidative and genotoxic stress, but only some compensatorystress responses are activated (DNA-PK–Akt–GSK3 pathway, chaperones). Many others seem to beinhibited, suggesting a blunted response to stress as component of DXR toxicity. (iii) Sarcomerestructure/function: We detect increased phosphorylation of desmin and reduced transcripts essentialfor e.g. normal heart development as potential causes for a disorganized myofibrillar network. Inconclusion, these results reveal some novel potential mechanisms of DXR-induced cardiotoxicity andsuggest new targets for protective strategies.

O meduloblastoma (MB) é o tumor cerebral maligno mais comum na infância. A formação/progressão desta neoplasia foi associada a alterações moleculares, que inclui a desregulação da via de sinalização Wingless (Wnt), responsável pelo desenvolvimento embrionário. Além disso, as proteínas da família Aurora-quinases (A, B e C) têm sido amplamente estudadas, uma vez que a Aurora A e B foram encontrados hiperexpressas em diversas neoplasias, como o MB. Estudos recentes mostraram que existe uma associação entre a Via Wnt e as Aurora-quinases. No entanto, poucos trabalhos foram realizados para confirmar essa associação. Ademais, não existem trabalhos que relatem os efeitos do AMG900, um pan-inibidor de aurora-quinases, em MB, dando enfoque na regulação da via Wnt. Assim, o objetivo deste trabalho foi avaliar a modulação da via Wnt pelo inibidor AMG900 nas linhagens celulares de meduloblastoma pediátrico. Foram realizados os ensaios de PCR convencional, sequenciamento, qRT-PCR, transfecção transiente, ensaio clonogênico, Western Blot e ciclo celular. As linhagens celulares UW402, UW473 e ONS-76 não apresentaram mutações no éxon 3 do gene CTNNB1 (?-catenina) e no éxon 15 do gene APC. Não foi observada uma expressão significativa de CTNNB1, confirmando que as linhagens não possuíam a via Wnt ativa. Com isso foi necessário a transfecção transiente com a ?- catenina. Após este ensaio, houve um aumento da expressão de CTNNB1, Ciclina D1 e CMyc nas três linhagens, o que não ocorreu com as Auroras A e B. No ensaio clonogênico foi observado uma redução do número de colônias nas linhagens UW473 e ONS-76. Observou-se um aumento da expressão proteica da ?-catenina, da Aurora A e B na UW473, o que ocorreu somente com a ?-catenina na linhagem ONS-76. Após o tratamento com o AMG900 ocorreu uma diminuição da expressão proteica de ?-catenina, da Aurora A e B em ambas as linhagens. A transfecção não alterou o percentil celular em G2/M na UW402 e UW473. Já na ONS-76 houve um aumento significativo em G2/M, e o AMG900 potencializou esse bloqueio apenas nessa linhagem. Os resultados sugerem que pode haver alguma relação entre a inibição das proteínas Aurora-quinases e a expressão de proteínas da via Wnt. / Medulloblastoma (MB) is the most common malignant brain tumor in childhood. Tumor formation/progression has been associated to molecular alterations that include dysregulation of signaling pathway Wingless (Wnt), responsible for embryonic development. In addition, cell cycle proteins Aurora-kinase (A, B and C) have been widely studied since Aurora A and B were found overexpressed in many cancers such as MB. Recent studies show that there is an association between Wnt pathway and Aurora kinase proteins. However, few studies have been conducted to confirm this association. Moreover, there are no studies reporting the effects of AMG900 in MB, by focusing on the regulation of the Wnt pathway. The aim of this study is to evaluate Wnt pathway modulation by Aurora kinases inhibitor AMG900 in pediatric medulloblastoma cell lines. Conventional PCR, sequencing, qRT-PCR, transient transfection, clonogenic assay, Western Blot and cell cycle assays were performed. UW402, UW473 and ONS-76 cell lines did not present mutations in exon 3 of CTNNB1 gene and exon 15 of APC gene. There was no significant expression of CTNNB1 and their target genes in these cell lines, confirming that they did not have Wnt pathway activated. Considering this, transient transfection was necessary. After this trial, there was an increase in expression of CTNNB1 gene and its target genes Cyclin D1 and C-Myc in the three cell lines, which was not observed in Aurora kinases. Furthermore, in the clonogenic assay, a reduction in the number of colonies in UW473 and ONS-76 cell lines was observed. It was also observed an increase in ?-catenin protein, Aurora A and B in UW473 cell line, but not in ONS-76 cell line. However, after treatment there was a decrease in protein expression of ?-catenin, Aurora A and B in both cells. Transfection did not change the cellular percentile in G2 / M in UW402 and UW473. In ONS-76 there was a significant increase in G2 / M, and the treatment with AMG900 potentiated this block only in this cell line. Results suggest that there may be some relation between the inhibition of Aurora kinase protein and protein expression in Wnt pathway.

Diversas alterações genéticas estão associadas à patogênese do carcinoma epidermoide (CE), neoplasia maligna mais comum de cabeça e pescoço. Algumas dessas alterações comprometem proteínas pertencentes à via de sinalização do Akt, envolvida em diferentes fenômenos celulares. Este trabalho teve como objetivo estudar a expressão da proteína pAkt em linhagens celulares de carcinomas epidermoides de cabeça e pescoço, de forma a verificar possíveis alterações na transcrição dessa molécula em células de CE tratadas com Curcumina. Foram utilizadas duas linhagens celulares de CE de cabeça e pescoço (FaDu e SCC9) e uma linhagem de queratinócitos normais (HaCat) divididas em dois grupos: a. Grupo controle não tratado; b. Células tratadas com Curcumina. A proliferação celular foi monitorada através do teste de viabilidade celular e a análise da expressão de proteína foi realizada através da técnica do Western Blotting que revelou supressão do pAkt na linhagem celular SCC9 nos tempos de 24 e 48 horas. Desta forma, conclui-se que a Curcumina na via do Akt em carcinomas epidermoides de cabeça e pescoço tem importante ação supressora do gene pAkt. / Several genetic alterations are associated with the pathogenesis of squamous cell carcinoma (SCC), the most common malignant neoplasm of the head and neck. Some of these changes compromise the proteins belonging to the Akt signaling pathway, involved in various cellular phenomena. The objective of this study to explores the expression of the pAkt protein in cell lines of the squamous cell carcinomas of the head and neck to verify possible changes in the transcription of this molecule in EC cells treated with curcumin. The study used two cell lines of EC head and neck (FaDu and SCC9) and a normal line of keratinocytes (HaCat), split into two groups: A. the controlled group, untreated; B. Cells treated with curcumin. The cell proliferation it was observed by cell viability test and analysis of protein expression performed through Western blotting technique revealed suppression of pAkt in SCC9 cell line at 24 and 48 hours. Thus, it is concluded that the Curcumin on the path of Akt in squamous cell carcinoma of the head and neck has a significant suppressive effect of gene Akt.

O overreaching não funcional (NFOR) induzido por consecutivas sessões de treinamentos intensos intercaladas por períodos insuficientes de recuperação, está associado com inflamação e consequente prejuízo da via de sinalização insulínica em músculos esqueléticos de camundongos. Sabe-se que o miocárdio também é capaz de produzir tais proteínas inflamatórias associadas ao comprometimento da via hormonal e que alterações na atividade do receptor insulínico cardíaco levam à forçadas modificações na utilização dos substratos energéticos com prejuízos na mecanoenergética cardíaca predispondo o miocárdio à diversas injúrias. No entanto os efeitos do NFOR nas vias inflamatórias e insulínica cardíaca ainda não foram investigados. Assim, o presente estudo tem como objetivo avaliar os efeitos do NFOR no conteúdo de glicogênio cardíaco e ativação de proteínas relacionadas às vias insulínica e inflamatória. Os animais foram divididos em 6 grupos: Naive, Controle, Treinado, e os grupos submetidos ao protocolo de overtraining em declive (OTR/down), aclive (OTR/up) e sem inclinação (OTR). As especificidades das contrações musculares induziram diferentes adaptações cardíacas. Os grupos OTR e OTR/up não apresentaram sinais de inflamação além de superexpressarem a via insulínica, por outro lado, o grupo OTR/down apresentou inflamação cardíaca de baixo grau, contudo, sem queda no conteúdo de pIR. Todos os protocolos de overtraining induziram elevação no conteúdo de glicogênio cardíaco acompanhado de expressiva queda da pAMPK. Os resultados do presente trabalho nos trazem, portanto, a hipótese de que o tecido cardíaco apresente uma maior resistência à inflamação viabilizando dessa forma a melhora da resposta insulínica e acúmulo do glicogênio cardíaco a fim de fornecer a energia necessária ao extenuante exercício físico evitando a lipotoxicidade cardíaca. Por outro lado, a queda da AMPK consequente do excessivo acúmulo de glicogênio cardíaco pode predispor o miocárdio à diversas injúrias, sendo necessários mais estudos na área. / Non-functional overreaching (NFOR) induced by consecutive intense training sessions interspersed by insufficient periods of recovery is associated with inflammation and a consequent impairment of the insulin signaling pathway in skeletal muscle of mice. It is known that the myocardium is also capable of producing such inflammatory proteins associated with the impairment of the hormonal pathway and that changes in cardiac insulin receptor activity lead to forced modifications in the use of energetic substrates with losses in cardiac mecanoenergética predisposing the myocardium to various injuries. However, the effects of NFOR on inflammatory and cardiac insulin pathways have not been investigated yet. Thus, the present study aims to evaluate the effects of NFOR on cardiac glycogen content and activation of proteins related to insulin and inflammatory pathways. The animals were divided into 6 groups: Naïve, Control, Trained, and the groups submitted to the overtraining protocol in decline (OTR/down), uphill (OTR /up) and without inclination (OTR). The specificities of muscle contractions induced different cardiac adaptations. OTR and OTR/up groups showed no signs of inflammation and an over expressive of the insulin pathway; on the other hand, the OTR/down group presented low-grade cardiac inflammation, however, without any decrease in the pIR content. All overtraining protocols induced elevation in cardiac glycogen content accompanied by significant drop in pAMPK. The results of the present work hypothesize that the cardiac tissue presents a greater resistance to inflammation, thus enabling the improvement of the insulin response and the accumulation of cardiac glycogen in order to provide the necessary energy to the strenuous physical exercise avoiding cardiac lipotoxicity. On the other hand, the decrease in AMPK due to the excessive accumulation of cardiac glycogen may predispose the myocardium to several injuries, and further studies in the area are required.

Schweinfurthins are a family of natural products with significant anti-cancer activities. They were originally identified in the National Cancer Institute (NCI) human 60 cancer cell line screening. The growth inhibition profile of schweinfurthins is distinct from other clinically used anti-cancer agents, indicating that they have a novel mechanism of action or have a previously unrecognized protein target. Previous studies showed that schweinfurthins affect multiple cellular processes in cancer cells. For example, schweinfurthins can alter cytoskeleton organization, induce ER stress and apoptosis, and inhibit the mevalonate pathway. The mevalonate pathway is responsible for the production of isoprenoids and cholesterol, which have been shown to play regulatory roles in the Hedgehog (Hh) signaling pathway. In this study, we found that the Hh signaling pathway in NIH-3T3 and SF-295 cells was inhibited by schweinfurthins. The supplementation of mevalonate and cholesterol partially restored Hh signaling, indicating that schweinfurthins inhibit Hh signaling partially by down-regulating the products from the mevalonate pathway. Interestingly, schweinfurthins in combination with cyclopamine, an inhibitor of the Hh singaling pathway, synergistically decreased cell viability. In order to better understand the underlying mechanism of the anti-cancer action of schweinfurthins, we attempted to identify the protein target of schweifnurthins. Affinity chromatography was performed to pull down the protein target. We found that schweinfurhtins bound to the M2 isoform of pyruvate kinase (PKM2) and inhibit its pyruvate kinase activity. Knockdown of PKM2 by siRNA increased the sensitivity of SF-295 cells to schweinfurthins. The inhibition of PKM2 by schweinfurthins led to a reduction in the rate of glycolysis in cancer cells. Fructose 1,6-bisphosphate (FBP), an activator of PKM2, could alleviate schweinfurthin-mediated inhibition on PKM2 and glycolysis. Notably, FBP could also partially reverse the reduction of cell viability in the presence of schweinfurthins. Taken together, these studies revealed the mechanism by which schweinfurthins inhibit Hh signaling. In addition, we uncovered PKM2 as a schwienfurthin target and highlighted the importance of glycolysis suppression as a mechanism of the anti-cancer action of schweinfurthins.

Most members of the PAS (PER-ARNT-SIM) protein family are transcription factors, mediating development and adaptive responses to the environment, such as circadian rhythms and toxin responses. Because the PAS domain mediates protein-protein interactions and functional cross-talk between distinct biological processes, we hypothesized that PAS genes in the circadian clockworks, namely Per1 and Per2, may be involved in development and toxin responses, which are modulated by other PAS members. To explore the possible role of clock genes in development, we examined mammary epithelial cells in vitro and the mouse mammary gland in vivo for evidences of changes in clock gene expression during different stages of development and differentiation. Our results showed that Per1 and Bmal1 expression were up-regulated in differentiated HC-11 cells, whereas Per2 mRNA levels were higher in undifferentiated cells. A similar differentiation-dependent profile of clock gene expression was observed in mouse mammary glands; Per1 and Bmal1 mRNA levels were elevated in late pregnant and lactating mammary tissues, whereas Per2 expression was higher in proliferating virgin and early pregnant glands. These data suggest that circadian clock genes may play a role in mouse mammary gland development. To examine clock gene function in toxin responses, we evaluated whether disruption or inhibition of Per1 and/or Per2 alters toxin-induced activity of the AhR signaling pathway in the mouse mammary gland and liver. We assessed the activation of the AhR signaling pathway in response to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR agonist, by analyzing the mRNA abundance of its two target genes, cytochrome P450, subfamily I, polypeptide 1 (Cyp1A1) and Cyp1B1. Our results showed that the targeted disruption of Per1, but not Per2, significantly increases the TCDD-induced p450 expression in the mammary gland and liver in vivo. Similar changes in TCDD-mediated p450 expression were observed in vitro using mammary primary cultures of mammary cells derived from from Per1ldc, Per2ldc and Per1ldc/Per2ldc mutant mice and Hepa1c1c7 cells subjected to siRNA-mediated inhibition of Per1 or Per2. These discoveries suggest that the clock gene Per1 may modulate toxin responses perhaps by functioning as a negative regulator for TCDD-mediated activation of the AhR signaling pathway.

Delta-like 1 Homologue (DLK1), a transmembrane protein of 383 amino acids, belongs to a family of epidermal growth factor (EGF)-like repeat-containing proteins that include Notch/Delta/Serrate, which are involved in cell fate determination. DLK1 is also known as preadipocyte factor-1, pG2, and FA-1, which are identical or polymorphic products of a single gene. Structural analysis revealed that DLK1 consists of an extracellular domain with six EGF-like repeats, a transmembrane domain, and an intracellular domain. The extracellular EGF-like region of DLK1 (DLK1-EC) can be released to the medium by the action of tumor necrosis factor alpha converting enzyme (TACE). DLK1 participates in various differentiation processes including adipogenesis, hematopoiesis, and adrenal gland differentiation. Besides, DLK1 overexpression was observed in patients with biliary atresia and in glioblastoma. Recently, the extracellular domain of thrombomodulin, which also contains six EGF¡Vlike structures, has been delineated to stimulate angiogenesis in vitro and in vivo. This prompted us to investigate whether DLK1-EC played a role in angiogenesis. To test such hypothesis, recombinant DLK1-EC was expressed and purified in E. coli. Adding DLK1-EC recombinant protein inhibited the adipogenesis of adipocytes-derived stem cells in a dose-dependent manner. Despite marginal effect on matrix-metalloproteinase secretion, exogenous DLK1-EC significantly stimulated the proliferation, motility and tube-forming capability of cultured endothelial cells. Above all, implantation of DLK1-EC-containing hydron pellets induced cornea neovascularization in a dose-dependent manner. Western blot analysis revealed that exogenous DLK1-EC induced angiogenesis through Notch1 activating downstream gene Hes1 and subsequently signaling such as Akt/eNOS, p38 MAPK, and ERK pathway to perform its function. Indeed, blockade of Notch1 signaling using £^-secretase inhibitor leads to decreased angiogenesis and inhibits DLK1 EC-induced endothelial cell tubular formation in vitro and in vivo. These findings indicate that DLK1-EC induced Notch1 activation mediated by £^-secretase and tansactivation Akt/eNOS pathway and that Notch1 is critical for DLK1 EC-induced angiogenesis. These results may bring further insights into the physiological and pathological functions of DLK1

Most members of the PAS (PER-ARNT-SIM) protein family are transcription factors, mediating development and adaptive responses to the environment, such as circadian rhythms and toxin responses. Because the PAS domain mediates protein-protein interactions and functional cross-talk between distinct biological processes, we hypothesized that PAS genes in the circadian clockworks, namely Per1 and Per2, may be involved in development and toxin responses, which are modulated by other PAS members. To explore the possible role of clock genes in development, we examined mammary epithelial cells in vitro and the mouse mammary gland in vivo for evidences of changes in clock gene expression during different stages of development and differentiation. Our results showed that Per1 and Bmal1 expression were up-regulated in differentiated HC-11 cells, whereas Per2 mRNA levels were higher in undifferentiated cells. A similar differentiation-dependent profile of clock gene expression was observed in mouse mammary glands; Per1 and Bmal1 mRNA levels were elevated in late pregnant and lactating mammary tissues, whereas Per2 expression was higher in proliferating virgin and early pregnant glands. These data suggest that circadian clock genes may play a role in mouse mammary gland development. To examine clock gene function in toxin responses, we evaluated whether disruption or inhibition of Per1 and/or Per2 alters toxin-induced activity of the AhR signaling pathway in the mouse mammary gland and liver. We assessed the activation of the AhR signaling pathway in response to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR agonist, by analyzing the mRNA abundance of its two target genes, cytochrome P450, subfamily I, polypeptide 1 (Cyp1A1) and Cyp1B1. Our results showed that the targeted disruption of Per1, but not Per2, significantly increases the TCDD-induced p450 expression in the mammary gland and liver in vivo. Similar changes in TCDD-mediated p450 expression were observed in vitro using mammary primary cultures of mammary cells derived from from Per1ldc, Per2ldc and Per1ldc/Per2ldc mutant mice and Hepa1c1c7 cells subjected to siRNA-mediated inhibition of Per1 or Per2. These discoveries suggest that the clock gene Per1 may modulate toxin responses perhaps by functioning as a negative regulator for TCDD-mediated activation of the AhR signaling pathway.